Say goodbye to dull, tired skin, and embrace a luminous glow that radiates health and vitality
However, both isoforms have demonstrated their effectiveness in ovarian function and metabolism in patients with PCOS
DISSECTION P938 - ESOC25-2421 CADASIL Argentine Registry (CADASILar): Establishing a Harmonized Clinical Protocol preliminary data Julieta Rosales 1 , Carolina Ardohain 2 , Juan Lopez 3 , Fabio Gonzalez 4 , Julian Alonso 5 , Valentin Selvaggi 6 , Diana Cristalli 7 , Ismael Calandri 2 1 Clinica Sagrada Familia-ENERI, Buenos Aires, Argentina, 2 FLENI, Buenos Aires, Argentina, 3 Sanatorio Los Arcos, Buenos Aires, Argentina, 4 Hospital Italiano de Bs As, Buenos Aires, Argentina, 5 Hospital Posadas, Buenos Aires, Argentina, 6 Hospital Ramos Meja, Buenos Aires, Argentina, 7 Centro Jesi, Buenos Aires, Argentina Background and Aims: CADASIL, a leading monogenic small vessel disease caused by NOTCH3 mutations, manifests with migraines, strokes, and cognitive decline
When NAD+ or peptide therapy is delivered in clinic, the product is handled to a medical standard, the route and pacing are controlled, and any reaction can be recognized and managed on the spot
Widely used in research settings requiring complex compound combinations
Research status Phase 3 complete for monotherapy and CagriSema
